Roche drug cocktail doubles chance of holding lung cancer at bay

Print pagePDF pageEmail page

ZURICH (Reuters) – Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented.


Reuters: Health News … More ادامه مطلب

Leave a Reply

Time limit is exhausted. Please reload CAPTCHA.